Organon rises as review finds no issues in past biosimilar purchases

Organon & Co.

20/02/2026 12:57

** Shares of healthcare firm Organon OGN.N rise 3.5% to $7.78 premarket

** Co says an independent review found no wrongdoing in how it recorded earlier purchases of biosimilars, which are lower‑cost versions of complex biologic drugs

**  Co says its board audit committee launched the review after concerns were raised about timing of past biosimilar purchases; review found no need to revise past SEC filings

** Co says the annual report for 2025 will be filed on time

** Shares down ~52% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))